舒肝解郁胶囊辅助治疗精神分裂症患者抑郁症状的临床观察

目的：探讨舒肝解郁胶囊辅助治疗精神分裂症患者抑郁症状的临床疗效及安全性.方法：伴抑郁症状的精神分裂症患者在服用阿立哌唑基础上随机分为研究组（舒肝解郁胶囊1.44g·d-1）和对照组（氟西汀20mg·d-1）,观察6周后采用卡尔加里抑郁量表（CDSS）、阳性和阴性症状量表（PANSS）、匹兹堡睡眠质量指数（PSQI）及副反应量表（TESS）评定并比较两组的疗效和安全性.结果：两组PANSS、CDSS、PSQI评分均显著下降（P〈0.01）;研究组CDSS、PSQI评分明显低于对照组（P〈0.05）,研究组失眠显著少于对照组（P〈0.01）.结论：舒肝解郁胶囊辅助治疗精神分裂症患者抑郁症状临床疗效显著,安全性好.

Clinical observation of shuganjieyu capsule in adjuvant therapy for depressive symptoms of schizophrenic patients

Objective：To investigate clinical efficacy and safety of shuganjieyu capsule in adjuvant therapy for depressive symptoms of schizophrenic patients. Methods：Based on aripiprazole, schizophrenic patients with depression were divided into research group （Shuganjieyu capsule, 1.44g/d ） and control group （fluoxetine, 20rag/d）. 6 weeks after the treatment, Calgary depression scale for schizophrenia （CDSS）, positive and negative symptom scale （PANSS）, Pittsburgh sleep quality index （PSQI）, and treat- ment emergent symptom scale （TESS） were used to assess the efficacy and safety. Results： The CDSS, PSQI and PANSS scores of the two groups decreased notably （ P〈0.01 ）. The CDSS and PSQI scores of research group were obviously lower than those of control group （ P〈0.05 ）. The sleep disorder of research group was lighter than that of control group （ P〈0.01 ）. Conclusions ： Shuganjieyu capsule in the adjuvant therapy for the depressive symptoms of the schizophrenic patients has an obvious curative effect and a good safety.